News Quartet of biotechs join Nasdaq after stellar IPOs Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.
News BlossomHill, Vogenx and Latigo reveal IPO plans Three more biotechs have revealed their intentions to list on Nasdaq - BlossomHill, Vogenx, and Latigo - as 2026 heads for a record IPO haul.
News Latigo raises $150m for non-opioid painkiller push Latigo has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million in a Series B.
News Freenome raises $254m for cancer tests, and other financings Our round-up of recent biotech financings is headed by a $254 million private financing for cancer blood test specialist Freenome, with sizeable rounds for Cogent Bioscien
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.